DiagnosTear
Screening and Monitoring Kit for Dry Eye Syndrome
Company Overview
Snapshot
Founded in September 2013 by Eran Eilat, DiagnosTear operates with 1–10 employees. The company has raised $4.58 million across 5 funding rounds from 2 investors. In December 2024, DiagnosTear became publicly listed on the CSE.
Business overview
DiagnosTear specializes in developing technology for the diagnosis and treatment of dry eye syndrome. The company's core product, the TeaRx assay, is designed to facilitate the diagnosis, treatment, and monitoring of dry eye syndrome by examining specific parameters in tear fluid. This assay utilizes reagents that create color reactions upon contact with tear film, enabling a semi-quantitative assessment of defining parameters. The test is carried out using a simple device placed under the lower eyelid to absorb tear fluid. DiagnosTear serves the healthcare industry, operating within the Health Tech & Life Sciences sector, specifically focusing on medical devices and diagnostics.
Strategic signal
In May 2026, DiagnosTear secured exclusive global rights to the CLARIFY Eye Imaging Platform for needle-free blood diagnostics. This strategic move signals the company's expansion beyond dry eye syndrome diagnostics into broader, non-invasive diagnostic technologies, potentially opening new market opportunities and enhancing its product portfolio for investors.
Log in to access full profile ›Company Intelligence Q&A
- What was a significant recent clinical development for DiagnosTear?
- In July 2026, DiagnosTear announced interim clinical study results demonstrating excellent correlation between its TeaRx Red Eye diagnostic and quantitative ELISA testing, indicating high efficiency for the product.
- What regulatory approvals did DiagnosTear recently receive?
- In February 2026, DiagnosTear announced regulatory approvals in France and initiated a study with AlyaTec for its TeaRx Red Eye diagnostic.
- What strategic partnership did DiagnosTear establish for market entry?
- In February 2026, DiagnosTear advanced its UK market entry through a commercial collaboration with Hanson Medical.
- What new technology did DiagnosTear license in May 2026?
- In May 2026, DiagnosTear secured exclusive global rights to the CLARIFY Eye Imaging Platform for needle-free blood diagnostics, expanding its diagnostic capabilities.
- When did DiagnosTear become a public company?
- DiagnosTear became publicly listed on the CSE in December 2024.